Well Told Grants

Grants / Department of Health and Human Services / National Institutes of Health

Glioblastoma Therapeutics Network (GTN) (U19 Clinical Trial Required)

Open Closes January 11, 2027 (72 days left) Opportunity RFA-CA-27-005

National Institutes of Health is offering grants of up to $700,000 to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. It expects to make about 4 awards worth $4.4 million in total. Applications close on January 11, 2027.

From the official notice on Grants.gov, last changed September 30, 2026. Checked October 31, 2026.

Key dates

PostedAugust 31, 2026
DeadlineJanuary 11, 2027
Archived by Grants.govMarch 11, 2027

Add the deadline to your calendar

Who can apply

This opportunity is open to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses.

Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility. Foreign Organizations/International Collaborations:Non-domestic (non-U.S.) Entities (Foreign Organization) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.

More grants for nonprofits, colleges and universities, state and local governments, tribes, small businesses, businesses.

Is this a realistic fit?

What the grant funds

Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) solicits applications for research on novel therapies for adult glioblastoma (GBM). The goal is to improve the treatment of adult GBM by developing novel effective agents that can cross the blood brain barrier (BBB) and testing them clinically. Successful early-stage trials of new drugs from this NOFO would transition seamlessly to later stage trials using well-established NCI clinical trial mechanisms. To implement this concept, a highly collaborative GBM Therapeutics Network (GTN) of cross-cutting teams will be established, each team capable of driving therapeutic agent(s) from pre-clinical development, through investigational new drugs (IND) studies, into pilot clinical studies in humans. Appropriate therapeutic agents include: (1) novel agents or (2) agents or combinations approved for other indications and repurposed for treatment of GBM following appropriate preclinical studies. The scope of the NOFO, from late pre-clinical through early (Phase 0/1) clinical studies, uniquely spans a gap in the GBM drug development process.

Category: Health.

How to apply

  1. Read the full notice and attachments on Grants.gov. The notice is the official source for deadlines and requirements.
  2. Make sure your organization has an active SAM.gov registration and Unique Entity ID; registration can take several weeks.
  3. Register on Grants.gov and submit through Workspace before the deadline and time given in the notice. Our application guide walks through each step.

Questions go to National Institutes of Health, GTN-contacts@nih.gov, 301-402-2541.

Open the official notice

Questions people ask

Who can apply for Glioblastoma Therapeutics Network (GTN) (U19 Clinical Trial Required)?

National Institutes of Health accepts applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.

What is the deadline for Glioblastoma Therapeutics Network (GTN) (U19 Clinical Trial Required)?

Closes January 11, 2027 (72 days left). Confirm the date and time in the official notice on Grants.gov.

How much funding is available?

Awards of up to $700,000 each. About $4.4 million in total across about 4 awards.

Similar open grants